Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pactÂ
Summit is currently developing Ivonescimab in combination with other drugs across several types of solid tumours.
Read Full Article
Pharma Tech
Novartis bets on autoimmune BiTEs through $7.8bn Abogen dealÂ
Unlike other therapies in this class, Abogen’s ABO2203 is designed to produce a T-cell engager protein in vivo through an mRNA-encoded system.
Read Full Article
Pharma Tech
Magazine: Keep it cool
In this issue: Key themes of CPHI 2026, the GLP-1 manufacturing shift, cold chain logistics, and more.
Read Full Article
Pharma Tech
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
Drug delivery’s next bottleneck is manufacturing capacity: scale, validation, and resilient supply chains.
Read Full Article
Pharma Tech
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
ET Pharma
Oct 3, 2026, 2:09 AM
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues
The company was seeking the US Food and Drug Administration's approval for denecimig to treat adults and children with hemophilia A, with or without inhibitors, a rare condition that prevents the blood from clotting properly.
ET Pharma
Oct 3, 2026, 2:02 AM
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
Novartis will gain exclusive rights to Abogen's experimental drug, ABO2203, and options to license other therapies based on Abogen's RNA technology. It will also have the option to license additional experimental medicines developed using Abogen's RNA platform.
ET Pharma
Oct 2, 2026, 6:17 PM
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
The companies said that they intend to begin with a late-stage trial testing the therapies in first-line triple-negative breast cancer
Pharma Tech
Oct 2, 2026, 1:30 PM
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pactÂ
Summit is currently developing Ivonescimab in combination with other drugs across several types of solid tumours.
Pharma Tech
Oct 2, 2026, 10:24 AM
Novartis bets on autoimmune BiTEs through $7.8bn Abogen dealÂ
Unlike other therapies in this class, Abogen’s ABO2203 is designed to produce a T-cell engager protein in vivo through an mRNA-encoded system.
ET Pharma
Oct 2, 2026, 10:02 AM
Sanofi bets up to $8 Bn on Regeneron’s Immunology pipeline in search for Dupixent successor
Sanofi will pay $1 billion upfront and up to $7 billion tied to development and regulatory milestones.. Both companies will share development and commercialisation costs, while profits from global sales will be shared on a 50:50 basis.
News
Latest industry coverage
Google News
Oct 3, 2026, 2:30 AM
From pharmacy to laboratory: India's leap into drug discovery - India Today
From pharmacy to laboratory: India's leap into drug discovery  India Today
Google News
Oct 3, 2026, 1:47 AM
New Albany lands Bayer campus with innovative pharmaceutical facility - WSYX
New Albany lands Bayer campus with innovative pharmaceutical facility  WSYX
Google News
Oct 3, 2026, 12:49 AM
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP - The Motley Fool
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJPÂ Â The Motley Fool
Google News
Oct 3, 2026, 12:33 AM
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP - Yahoo Finance
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJPÂ Â Yahoo Finance
Google News
Oct 3, 2026, 12:30 AM
We Don't Have a Jobs Problem, We Have a Wages Problem: TeamLease's Manish Sabharwal On Employed Poverty - thecore.in
We Don't Have a Jobs Problem, We Have a Wages Problem: TeamLease's Manish Sabharwal On Employed Poverty  thecore.in
Google News
Oct 2, 2026, 11:48 PM
PharmTech AI Pulse Check: Episode 2 - Shadow AI, Trade Secrets, the API Race - pharmtech.com
PharmTech AI Pulse Check: Episode 2 - Shadow AI, Trade Secrets, the API Race  pharmtech.com
Google News
Oct 2, 2026, 9:52 PM
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues - Reuters
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues  Reuters
Google News
Oct 2, 2026, 9:31 PM
Iowa AG seeks court approval for $1.38M settlement with drug company - KTVO
Iowa AG seeks court approval for $1.38M settlement with drug company  KTVO
Google News
Oct 2, 2026, 9:07 PM
eli lilly and novo nordisk will discount their weight-loss drugs - BusinessWorld Online
eli lilly and novo nordisk will discount their weight-loss drugs  BusinessWorld Online
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer